Polaryx Therapeutics, Inc. Common Stock Stock Analysis & AI Score
Polaryx Therapeutics, Inc. Common Stock (PLYX) has an ST Score of 49.3 (C+), driven by its Financial Strength (A+) and held back by its Growth (F). PLYX last traded at $2.14.
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Polaryx Therapeutics, Inc. Common Stock (PLYX) has an ST Score of 49.3 (C+), driven by its Financial Strength (A+) and held back by its Growth (F). PLYX last traded at $2.14.
- Strongest
- Financial StrengthA+
- Weakest
- GrowthF
All factor grades
- Financial StrengthA+
- ForecastA
- ValuationB-
- MomentumC+
- ProfitabilityD+
- GrowthF
- Piotroski3/9
Contact
PLYX stock: frequently asked questions
What is PLYX's ST Score?
Polaryx Therapeutics, Inc. Common Stock (PLYX) has an ST Score of 49.3 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is PLYX a buy, hold, or sell?
Our ST Score grades it C+ (49.3/100). The ST Score is a data-driven signal, not a recommendation.
What are PLYX's factor grades?
Valuation B-, Profitability D+, Financial Strength A+, Momentum C+, Growth F, Forecast A.
What is PLYX's valuation grade?
Polaryx Therapeutics, Inc. Common Stock (PLYX) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is PLYX's growth grade?
Polaryx Therapeutics, Inc. Common Stock (PLYX) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is PLYX's profitability grade?
Polaryx Therapeutics, Inc. Common Stock (PLYX) earns a profitability grade of D+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is PLYX's financial strength grade?
Polaryx Therapeutics, Inc. Common Stock (PLYX) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for PLYX?
The average analyst price target for Polaryx Therapeutics, Inc. Common Stock (PLYX) is $6.50, which is +203.7% versus the recent price of $2.14.
What is PLYX's Piotroski score?
Polaryx Therapeutics, Inc. Common Stock (PLYX) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.